Grass pollen-derived allergy immunotherapeutic - ASIT Biotech

Drug Profile

Grass pollen-derived allergy immunotherapeutic - ASIT Biotech

Alternative Names: gp-ASIT+™; gpASIT+

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator BioTech Tools
  • Class Allergens; Allergy immunotherapies; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunosuppressants; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic rhinoconjunctivitis

Most Recent Events

  • 28 Feb 2017 Efficacy data from phase III trial in Allergic rhinoconjunctivitis released by ASIT biotech
  • 14 Nov 2016 ASIT biotech plans to submit BLA application with the US FDA for Allergic rhinoconjunctivitis
  • 15 Sep 2016 BioTech Tools completed a phase III trial in Allergic rhinoconjunctivitis in Belgium, Czech Republic, Italy, Spain, Germany, France (SC) (EudraCT2015-002105-11)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top